The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

ASCO 2021 Updates on De-Escalation Strategies in BC: Talazoparib for gBRCA1/2 Operable TNBC, Neoadjuvant Trastuzumab & Pertuzumab +/- Paclitaxel for HER2+/HR− EBC

68 views
July 22, 2021
Comments 0
Login to view comments. Click here to Login